GSK plc reports

Company location
London
GSK plc has filed 6,784 SEC EDGAR filings since 12 Jan 2001

SEC filing history

Showing 151-175 of 1,000 matching filings.

Per page
25
Current page
7
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
17 Feb 2026
Reporting date
17 Feb 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR File 028-26280

13F-HR filing

Filing date
12 Feb 2026
Reporting date
31 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
11 Feb 2026
Reporting date
11 Feb 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
11 Feb 2026
Reporting date
11 Feb 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
11 Feb 2026
Reporting date
11 Feb 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
11 Feb 2026
Reporting date
11 Feb 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

CHINA CDE ACCEPTS AREXVY ADULTS 60+ APPLICATION

Filing date
10 Feb 2026
Reporting date
10 Feb 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
09 Feb 2026
Reporting date
09 Feb 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
06 Feb 2026
Reporting date
06 Feb 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

NUCALA COPD APPROVED BY THE EUROPEAN COMMISSION

Filing date
06 Feb 2026
Reporting date
06 Feb 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
05 Feb 2026
Reporting date
05 Feb 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

FINAL RESULTS

Filing date
04 Feb 2026
Reporting date
04 Feb 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date
02 Feb 2026
Reporting date
02 Feb 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

EUROPEAN COMMISSION APPROVES AREXVY FOR ADULTS 18+

Filing date
26 Jan 2026
Reporting date
26 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SC TO-C

SC TO-C

Filing date
20 Jan 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC TO-C

SC TO-C

Filing date
20 Jan 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK TO ACQUIRE RAPT THERAPEUTICS

Filing date
20 Jan 2026
Reporting date
20 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

AGREEMENT ON CHANGES TO VIIV MINORITY SHAREHOLDING

Filing date
20 Jan 2026
Reporting date
20 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
16 Jan 2026
Reporting date
16 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
15 Jan 2026
Reporting date
15 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
13 Jan 2026
Reporting date
13 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

EC APPROVAL OF SHINGRIX PFS

Filing date
07 Jan 2026
Reporting date
07 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

POSITIVE PHASE 3 DATA FOR GSK'S BEPIROVIRSEN

Filing date
07 Jan 2026
Reporting date
07 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

EXDENSUR APPROVED IN JAPAN

Filing date
06 Jan 2026
Reporting date
06 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .